新抗原市場規模、佔有率和成長分析：按療法、癌症類型、發展階段、最終用戶、技術和地區分類－2026-2033年產業預測

2024 年全球新抗原市場價值為 18.7 億美元，預計到 2025 年將成長至 22.1 億美元，到 2033 年將成長至 85.6 億美元，在預測期（2026-2033 年）內複合年成長率為 18.4%。

全球新抗原市場專注於腫瘤特異性突變肽的發現、生產和臨床應用，這些突變肽因其能夠在不損傷健康組織的情況下誘導強效免疫反應而備受青睞。在基因測序、生物資訊學和胜肽合成技術進步的推動下，該市場正經歷著翻天覆地的變化，從一個小眾研究領域轉型為充滿活力的商業市場。監管支援至關重要，因為清晰的核准路徑將增強投資者信心，並鼓勵創業投資投資於利用人工智慧驅動的表位篩選技術的創新公司。這項技術能夠加速設計和生產流程，縮短研發週期，並加快臨床前檢驗。隨著醫院將新抗原臨床試驗納入其腫瘤治療方案，投資將會增加，研究將蓬勃發展，保險報銷機會也將擴大。

全球新抗原市場的成長要素

全球新抗原市場的主要促進因素是全球癌症發生率的上升以及由此帶來的對個人化免疫療法需求的成長。傳統癌症療法的療效往往有限，且可能產生嚴重的副作用，因此人們越來越關注利用腫瘤特異性突變的標靶治療。由這些突變產生的新抗原為調節免疫反應以特異性攻擊癌細胞提供了一個很有前景的方法。人們對個人化醫療日益成長的興趣，加上基因測序技術的進步，正在加速基於新抗原的療法的研發，並推動市場成長。

全球新抗原市場的限制因素

全球新抗原市場面臨的主要阻礙因素是新抗原發現和檢驗過程的複雜性和漫長性。開發個人化新抗原療法需要大量的研究和先進的技術，這極其耗資且耗時。此外，法規核准的挑戰和嚴格的臨床試驗要求也會進一步阻礙市場成長。對先進生物資訊工具的需求以及患者腫瘤特徵的差異性增加了複雜性，使得企業難以有效地擴大生產規模。這些因素可能導致投資猶豫，並減緩新抗原療法在臨床實踐中的整體應用。

全球新抗原市場趨勢

全球新抗原市場正經歷著向個人化免疫抗原性平台的顯著轉變，這主要得益於高通量定序和人工智慧驅動的表位預測技術的進步。這些創新使得快速識別患者特異性新抗原成為可能，從而將治療應用範圍從傳統的黑色素瘤治療擴展到包括肺癌、大腸直腸癌和卵巢癌等多種固體癌。這一趨勢正在促進生物技術公司、診斷服務供應商和學術機構之間的合作生態系統，加速整合研發管線的開發，優先為每位患者提供個人化免疫療法。這項策略重點旨在簡化研發流程，同時確保符合監管標準並維護全球病患安全。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球新抗原市場規模：依治療類型分類

• 個人化新抗原疫苗
• 共用新抗原疫苗
• 基於新抗原的T細胞療法
• 聯合治療

全球新抗原市場規模：依癌症類型分類

• 黑色素瘤
• 非小細胞肺癌
• 結腸癌
• 乳癌
• 其他

全球新抗原市場規模：依發展階段分類

• 發現階段
• 臨床前階段
• 臨床階段
• 商業

全球新抗原市場規模：依最終用戶分類

• 生技公司
• 製藥公司
• 學術研究機構
• 癌症中心

全球新抗原市場規模：依技術分類

• DNA定序
• 生物資訊平台
• 人工智慧驅動的新抗原預測
• 其他

全球新抗原市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• BioNTech SE
• Moderna, Inc.
• Gritstone bio, Inc.
• Genentech, Inc.
• Nouscom AG
• Evaxion Biotech A/S
• Geneos Therapeutics, Inc.
• Transgene SA
• CureVac NV
• Bavarian Nordic A/S
• NEC Corporation
• Ultimovacs ASA
• Personalis, Inc.
• Tempus AI, Inc.
• Illumina, Inc.
• QIAGEN NV
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Encode Medicine, Inc.
• Anixa Biosciences, Inc.

結論與建議

Global Neoantigen Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 2.21 Billion in 2025 to USD 8.56 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The global neoantigen market focuses on the discovery, manufacturing, and clinical implementation of cancer vaccines targeting tumor-specific mutated peptides, highlighting their ability to elicit strong immune responses without harming healthy tissue. This market has evolved significantly, driven by advances in genomic sequencing, bioinformatics, and peptide synthesis, transforming it from a niche research area into a dynamic commercial sector. Regulatory support is vital, as clear pathways for approval enhance investor confidence and drive venture capital toward innovative firms utilizing AI-driven epitope selection. This technology expedites the design and manufacturing processes, shortening development timelines and increasing preclinical validation speed. As hospitals integrate neoantigen trials into oncology treatment protocols, investments will rise, stimulating research and expanding reimbursement opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neoantigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neoantigen Market Segments Analysis

Global neoantigen market is segmented by therapy type, cancer type, development stage, end user, technology and region. Based on therapy type, the market is segmented into Personalized Neoantigen Vaccines, Shared Neoantigen Vaccines, Neoantigen-Based T Cell Therapies and Combination Therapies. Based on cancer type, the market is segmented into Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer and Others. Based on development stage, the market is segmented into Discovery, Preclinical, Clinical and Commercial. Based on end user, the market is segmented into Biotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes and Cancer Centers. Based on technology, the market is segmented into DNA Sequencing, Bioinformatics Platforms, AI-Based Neoantigen Prediction and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neoantigen Market

A key market driver for the global neoantigen market is the increasing prevalence of cancers worldwide and the subsequent demand for personalized immunotherapies. As conventional cancer treatments often exhibit limited effectiveness and can cause significant side effects, there is a growing emphasis on targeted therapies that leverage the unique mutations present in individual tumors. Neoantigens, which arise from these mutations, represent a compelling approach for tailoring immune responses to attack cancer cells specifically. This heightened focus on personalized medicine, combined with advancements in genomic sequencing technologies, is driving research and development in neoantigen-based therapies, propelling market growth.

Restraints in the Global Neoantigen Market

A significant restraint in the global neoantigen market is the complex and lengthy process of neoantigen discovery and validation. Developing personalized neoantigen-based therapies demands extensive research and sophisticated technologies, which can be cost-prohibitive and time-consuming. Additionally, challenges related to regulatory approval and the need for rigorous clinical trials can further hinder market growth. The requirement for advanced bioinformatics tools and the variability in patient tumor profiles add layers of complexity, making it difficult for companies to scale production effectively. These factors may deter investment and slow down the overall adoption of neoantigen therapies in clinical settings.

Market Trends of the Global Neoantigen Market

The Global Neoantigen market is experiencing a significant shift towards personalized immunogenic platforms, driven by advancements in high-throughput sequencing and AI-based epitope prediction technologies. These innovations are facilitating the rapid identification of patient-specific neoantigens, which are extending therapeutic applications beyond traditional melanoma treatments to encompass various solid tumors, including lung, colorectal, and ovarian cancers. This trend is prompting a collaborative ecosystem among biotech companies, diagnostic providers, and academic institutions, fostering the development of integrated pipelines that prioritize the delivery of tailored immunotherapies. This strategic focus aims to streamline development timelines while ensuring compliance with regulatory standards and maintaining patient safety on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neoantigen Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Personalized Neoantigen Vaccines
• Shared Neoantigen Vaccines
• Neoantigen-Based T Cell Therapies
• Combination Therapies

Global Neoantigen Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Melanoma
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

Global Neoantigen Market Size by Development Stage & CAGR (2026-2033)

• Market Overview
• Discovery
• Preclinical
• Clinical
• Commercial

Global Neoantigen Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biotechnology Companies
• Pharmaceutical Companies
• Academic & Research Institutes
• Cancer Centers

Global Neoantigen Market Size by Technology & CAGR (2026-2033)

• Market Overview
• DNA Sequencing
• Bioinformatics Platforms
• AI-Based Neoantigen Prediction
• Others

Global Neoantigen Market Size & CAGR (2026-2033)

• North America (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • US
  • Canada
• Europe (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nouscom AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evaxion Biotech A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geneos Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NEC Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultimovacs ASA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus AI, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Encode Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anixa Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations